PhecdaMed
Latest round
- Series A
Last raised
- Sep 2025
Total raised
- Undisclosed
Investors
- 7
About PhecdaMed
Based in Hangzhou, China, and founded in 2021, PhecdaMed operates as a biopharmaceutical developer, specializing in mitochondrial research. The chief scientist as well as the chairman of the board, Hongguang Xia, is the vice chairman of the Biomedical Branch of the SCOC. The co-founder, Dong Liu, was the Associate Director of Hangzhou Tigermed Consulting Company Limited. In March 2023, the company was recognized as a National Science and Technology-based Small and Medium-sized Enterprise (SME).S. Food and Drug Administration (FDA). The company focuses on the small molecule selective mitochondrial autophagy inducers and tumor immune enhancers. It launched mitochondrial autophagy inducer small molecule compound TJ0113. The drug can be used in curing kidney disease, autoimmune disease, and aging-related diseases. Revenue is generated from licensing of drug candidates, government grants, and strategic partnerships with pharmaceutical companies.
Who invested in PhecdaMed
7 investors across 3 rounds
See all investors in PhecdaMed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about PhecdaMed
Who invested in PhecdaMed?
PhecdaMed has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has PhecdaMed raised?
PhecdaMed has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did PhecdaMed last raise money?
PhecdaMed's most recent round on record is a Series A, in Sep 2025.
What does PhecdaMed do?
Based in Hangzhou, China, and founded in 2021, PhecdaMed operates as a biopharmaceutical developer, specializing in mitochondrial research.
Where is PhecdaMed headquartered?
PhecdaMed is headquartered in Hangzhou, China.
Which VCs invest in companies like PhecdaMed?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at PhecdaMed's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like PhecdaMed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.